has Server used IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 1999-10-26 (20 years, 288 days) and hosted in Ann Arbor United States, server ping response time 62 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Viacyte keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Viacyte ipo
2 Viacyte
3 Viacyte ceo
4 Viacyte 2019
5 Viacyte jobs
6 Viacyte logo
7 Viacyte fails
8 Viacyte news
9 Viacyte study

Hosting Provider

Region: MI
City: Ann Arbor
Postal Code: 48104
Latitude: 42.273399353027
Longitude: -83.713302612305
Area Code: 734
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain

New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » (8 seconds ago)

   » (32 seconds ago)

   » (4 seconds ago)

   » (1 min ago)

   » (17 seconds ago)

   » (2 seconds ago)

   » (14 seconds ago)

   » (1 seconds ago)

   » (0 seconds ago)

   » (18 seconds ago)

Results For Websites Listing

Found 73 Websites with content related to this domain, It is result after search with search engine

ViaCyte | Regenerative Medicine Therapies for Diabetes

(2 day ago) Developing a Functional Cure for Type 1 Diabetes. ViaCyte is a regenerative medicine company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for all type 1 diabetes and a next-generation treatment for insulin-requiring type 2 diabetes.

DA: 11 PA: 11 MOZ Rank: 12

Leadership - ViaCyte

(2 day ago) Kevin D’Amour, Ph.D. Vice President, Research Chief Scientific Officer . Kevin D’Amour, Ph.D. is an expert in stem cell science, an inventor of ViaCyte’s key patents, and a co-author of high profile publications in renowned scientific journals.

DA: 11 PA: 12 MOZ Rank: 23

ViaCyte - Home | Facebook

(1 day ago) ViaCyte. 3,120 likes · 69 talking about this · 133 were here. ViaCyte is a regenerative medicine company dedicated to developing a functional cure for type 1 diabetes. #T1D #diabetes

DA: 16 PA: 8 MOZ Rank: 24

ViaCyte - Crunchbase Company Profile & Funding

(5 day ago) ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device.

DA: 18 PA: 21 MOZ Rank: 39

ViaCyte Inc - Company Profile and News - Bloomberg Markets

(4 day ago) ViaCyte, Inc. develops and commercializes cell therapies to treat diabetes. The Company provides human embryonic stem cells for Type 1 and Type 2 diabetic patients, as well as therapies based on

DA: 17 PA: 28 MOZ Rank: 45

ViaCyte | VentureRadar

(27 day ago) "ViaCyte, Inc., a leader in the emerging field of regenerative medicine, is headquartered in San Diego, California. ViaCyte's innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors (PEC-01™), with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device (Encaptra

DA: 20 PA: 50 MOZ Rank: 78

Working at ViaCyte | Glassdoor

(2 month ago) Glassdoor gives you an inside look at what it's like to work at ViaCyte, including salaries, reviews, office photos, and more. This is the ViaCyte company profile.,18.htm

DA: 17 PA: 50 MOZ Rank: 68


(2 month ago) ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia

DA: 15 PA: 6 MOZ Rank: 21


(2 month ago) Paul Laikind, Ph.D., President & CEO San Diego, CA (Private) ViaCyte is a privately held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.

DA: 15 PA: 6 MOZ Rank: 21

First Human Trial of Stem Cell-derived Implants Underway

(8 day ago) The Center for Beta Cell Therapy in Diabetes and ViaCyte, Inc., announced that a human stem cell-derived product candidate has been implanted in type 1 diabetes patients at a subtherapeutic dose. These are the first patients in Europe to receive PEC-Direct, an encapsulated pancreatic progenitor cell product candidate designed to replace lost insulin-producing beta cells and restore blood […]

DA: 9 PA: 50 MOZ Rank: 96

Recently Analyzed Sites